Medical News

RSS

Highlight Therapeutics presents positive Phase 2b topline results of intralesional BO‑112 in localized basal cell carcinoma as a late-breaker at EADV

Highlight Therapeutics, a clinical‑stage biotechnology company developing immune activators to transform the treatment of skin tumors, today announced positive results from the multicenter, single-arm Phase 2b SPOTLIGHT‑204 clinical trial evaluating BO‑112, a novel dsRNA-based intralesional treatment for patients with resectable primary low‑ and high‑risk basal cell carcinoma (BCC).

1 Oct 2026

Do you really need to fast before a blood test? It depends on the test

The impact of fasting on blood test results is analyte-specific, with most routine tests showing minimal differences, suggesting a need for flexible guidelines.

1 Oct 2026

Cognitive tests may not tell the whole story about memory concerns

This study highlights the link between blood biomarkers and dementia risk in subjective cognitive decline, emphasizing prevention and lifestyle changes.

1 Oct 2026

Esophageal cancer leaves a distinct metabolic signature in the gut

The study uncovers gut microbial and metabolic signatures in esophageal cancer, emphasizing lipid dysregulation and its potential role in disease progression.

1 Oct 2026

Novel surgical technique restores clitoral sensation using buccal mucosa graft

For women who lose part of their clitoris because of vulvar cancer, a clitoral reconstruction procedure has now been developed for the first time. This comes forty years after the first penile reconstruction surgery. Results in the initial group of patients are encouraging.

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Study examines driving cessation in dementia and MCI

Flinders University researchers have investigated the reactions of people with dementia and mild cognitive impairment (MCI), in the hope of finding a process that best supports the person with dementia.

1 Oct 2026

Early-onset type 2 diabetes trial demonstrates significant 24-week fat loss

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Regional Health Americas journal shows that in people who have developed early onset type 2 diabetes (EOT2D) (aged under 45 years), around half these T2D cases can be reversed with a low-energy diet combined with a structured exercise program.

1 Oct 2026

Fluorescent sensors could help researchers see diabetes in action

Researchers from the University of Bath have developed fluorescent molecular probes that can detect changes in glucose levels inside living animals, giving scientists new ways of visualizing sugar uptake, studying diabetes, cancer and other metabolic diseases in whole organisms in real time.

1 Oct 2026

Honeybee silk could power smarter wound dressings

Biodegradable films made from engineered honeybee silk could form the basis of a new generation of ‘smart’ wound dressings, according to CSIRO and Adelaide University researchers.

1 Oct 2026

OnDosis and Adare Pharma Solutions announce strategic collaboration to advance OnDosis's lead U.S. ADHD program

OnDosis AB ("OnDosis"), a Swedish life science company developing drug device combinations for precision dosing of oral solid medicines based on the Dosage Manager device platform, and Adare Pharma Solutions ("Adare"), a technology-driven, integrated contract development and manufacturing organization (CDMO), today announced a strategic collaboration.

From OnDosis AB 1 Oct 2026

New antibiotic combinations aim to prevent recurrent bacterial vaginosis

Researchers and clinicians from Monash University and Bayside Health's Melbourne Sexual Health Centre are trialing new combinations of antibiotics to treat persistent bacterial vaginosis (BV), following their landmark discovery that the condition is sexually transmissible.

30 Sep 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Menstrual tracking apps lack evidence of health and performance benefits

Digital menstrual tracking risks creating more harm than benefit and requires greater scrutiny, warn experts in The BMJ today.

30 Sep 2026

Insurance hurdles and costs hinder access to blood cancer drugs

Patients with blood cancers often face major insurance hurdles and significant out-of-pocket costs when trying to access specialty oral anticancer medications, according to a new nationwide study led by researchers at the Perelman School of Medicine at the University of Pennsylvania.

30 Sep 2026